ReviewFrontiers in pharmacology2021
Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Methotrexate Exposure and Inflammatory-Metabolic Biomarker Networks in Hospitalized Patients with Psoriasis: A Network Analysis Approach.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review.Cureus · 2026Review
- Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series.Frontiers in medicine · 2026Article
- Reduced Fibrinolysis Links Obesity to Cardiovascular Risk in Psoriasis Independently of Inflammation: A Novel Mechanistic Pathway.Acta dermato-venereologica · 2025Article
- Cardiovascular Risk in Autoimmune Diseases: Mechanisms, Management, and Emerging Evidence.Cureus · 2025Review
- Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.Journal of clinical medicine · 2025Article
- Review
- Psoriasis: an emerging risk factor for ischemic stroke?Frontiers in neurology · 2025Review
- Residual metabolic burden in young psoriasis patients successfully treated with biologics.Archives of dermatological research · 2024Article
- Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program.Scientific reports · 2024Article
- A Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome.Clinical, cosmetic and investigational dermatology · 2024Article
- Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review.Clinical, cosmetic and investigational dermatology · 2023Review
- The Implication of Misinformation and Stigma in Age-Related Quality of Life, Depression, and Coping Mechanisms of Adult Patients with Psoriasis.Medicina (Kaunas, Lithuania) · 2022Article
- Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics.Pharmaceuticals (Basel, Switzerland) · 2022Review
- What Can IBD Specialists Learn from IL-23 Trials in Dermatology?Journal of Crohn's & colitis · 2022Review
- Psoriasis and Systemic Inflammatory Disorders.International journal of molecular sciences · 2022Review
- Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The cardiometabolic conditions of psoriatic disease.Frontiers in immunology · 2022Review
- Toward Personalized Interventions for Psoriasis Vulgaris: Molecular Subtyping of Patients by Using a Metabolomics Approach.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities. In particular, the association between psoriasis and cardiometabolic comorbidities, including cardiovascular diseases (CVDs), obesity, diabetes mellitus, and metabolic syndrome, has been verified in a considerable number of clinical trials. Moreover, the increased risk of cardiometabolic comorbidities positively correlates with psoriasis severity. Biologic therapy targeting inflammatory pathways or cytokines substantially improves the life quality of psoriasis patients and may affect cardiometabolic comorbidities by reducing their incidences. In this review, we focus on exploring the association between cardiometabolic comorbidities and psoriasis, and emphasize the benefits and precautions of biologic therapy in the management of psoriasis with cardiometabolic comorbidities. The pathogenic mechanisms of cardiometabolic comorbidities in psoriasis patients involve common genetic factors, lipid metabolism, insulin resistance, and shared inflammatory pathways such as tumor necrosis factor-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.